Abstract
Myopia is a significant epidemic endangering public health in the world, and the necessity to control it results in the development of effective guidelines. This is the critical review of next-generation Progressive Addition Lenses (PALs), which actively oppose the development of myopia with the help of innovative optical systems, as opposed to the usual corrective lenses.Based on the recent randomized controlled trials, it concludes that two types of evidence-based Defocus Incorporated Multiple Segments (DIMS/Hoya MiyoSmart) and Highly Aspherical Lenseslets (H.A.L./Essilor Stellest) are highly effective. These lenses show a reduction of 52-67percent of refraction progression of the sphere equivalent and 60-62 percent when it comes to the refraction of the axial elongation in two years as compared to the single version lenses. Maximum efficacy is among young children. Their main action is the establishment of peripheral consistent myopic defocus. Next-generation PALs have the same level of effectiveness as other popular interventions, such as orthokeratology and low-dose atropine, and a better safety profile and high adherence. The evidence confirms that these lenses are an extremely useful, safe and economic first line treatment of childhood myopia and a means of reducing the risk of later onset of complications that are a threat to the child and of which is a deterrent to future vision.